Elanco Animal Health (NYSE:ELAN) Issues Earnings Results

Elanco Animal Health (NYSE:ELAN) posted its quarterly earnings results on Thursday. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01, Briefing.com reports. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The company’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.18 EPS.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded down $0.43 during trading on Friday, hitting $14.07. 6,323,568 shares of the stock traded hands, compared to its average volume of 4,403,132. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The company has a fifty day moving average price of $13.93 and a two-hundred day moving average price of $14.72. Elanco Animal Health has a 52-week low of $10.19 and a 52-week high of $18.80.

Analysts Set New Price Targets

ELAN has been the subject of a number of research reports. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus restated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Barclays increased their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and a consensus price target of $17.14.

Insider Buying and Selling

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the transaction, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The trade was a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. This represents a 200.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael J. Harrington purchased 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was bought at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the purchase, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.